Birkbeck, University of London Featured PhD Programmes
University of Kent Featured PhD Programmes
Sheffield Hallam University Featured PhD Programmes
Engineering and Physical Sciences Research Council Featured PhD Programmes
Cardiff University Featured PhD Programmes

Novel targeted cytotoxic chemotherapy for prostate cancer

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  • Full or part time
    Dr Steven Shnyder
    Prof Paul Loadman
    Dr Rob Falconer
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

This is one of three new fully-funded PhD studentships in the new Institute of Cancer Therapeutics Doctoral Training Centre (ICT-DTC) at the University of Bradford. Focused on the generation of new anticancer prodrugs, the ICT-DTC has been created following a major £2m investment by ICT spin-out company Incanthera Ltd.

Project Background
Taxanes (docetaxel, paclitaxel) are the single most important treatment for men with advanced prostate cancer, but consistently cause dose-limiting toxicities. There is, therefore, a need to develop novel strategies to optimise taxane therapy. Membrane-type matrix metalloproteinases (MT-MMPs) are functionally active at high levels in prostate cancer tissue, have negligible activity in normal tissue, and selectively cleave specific peptide sequences. In preliminary studies, we demonstrated proof-of-concept for an MT-MMP-activated taxane (paclitaxel) prodrug, ICT3205, in a prostate cancer model.

Aim
To develop a new non-toxic prodrug therapy for prostate cancer

Focus
Optimisation of our prototype prodrug, ICT3205. Fine-tuning of MT-MMP peptide sequence selectivity, and chemical modifications to enhance aqueous solubility. Evaluation of prodrug stability in normal tissues, prodrug activation in tumour tissues; MMP cleavage; assessment of aqueous solubility. Pilot pharmacokinetics study in mice for most promising compound.

Funding Notes

Studentships cover tuition fees, a tax free stipend (at standard MRC rates, £15,009 per annum 2019/20) for the duration programme and writing-up (3.5 years total) and a generous research budget. A travel fund is also provided for each student to guarantee participation in a national and international conference. Funding for specific training courses is also included in the DTC.

References

Entry requirements

At least 2:1 honours degree or equivalent in Chemistry, Medicinal Chemistry, Pharmacy or related subjects. A relevant Masters degree would be viewed favourably.
For full details of our entry requirements, please visit our website.



FindAPhD. Copyright 2005-2019
All rights reserved.